Development of CD44E/s dual-targeting DNA aptamer as nanoprobe to deliver treatment in hepatocellular carcinoma.

Nanotheranostics · 2022 · PMC8671951 · PMID 34976591

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Compared to the normal liver tissue reference pool, both isoforms showed an increasing trend of expressions with a median 4.2-fold (CD44E) and ~2-fold (CD44s) upregulations detected in tumors ( Figure 1 B ).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.